In the context of his work at the University of Salzburg, BOEHMERT & BOEHMERT patent attorney Dr. Jan B. Krauß has published an article as co-author on the topic “Drug Development for Target Ribosomal Protein rpL35/uL29 for Repair of LAMB3R635X in Rare Skin Disease Epidermolysis Bullosa”.
In the scientific paper, atazanavir and artesunate are identified as candidate compounds that bind to the ribosomal protein rpL35. The compounds are currently being tested for their potential to trigger a rpL35 ribosomal switch to increase the production of full-length Lamb3 protein from a LAMB3PTC mRNA. This serves as a targeted systemic therapy in treating the rare genetic blistering skin disorder severe junctional epidermolysis bullosa.
Dr. Krauß published the article together with A. Rathner, P. Rathner, A. Friedrich, M. Wießner, CM. Kitzler, J. Schernthaner, T. Karl, F. Lottspeich, W. Mewes, H. Hintner, JW. Bauer, M. Breitenbach, N. Müller, H. Breitenbach-Koller and J. von Hagen.
It may be read in the July 2021 issue, Vol. 34, No. 4, of the scientific journal “Skin Pharmacology and Physiology” published by S. Karger AG and can be purchased here.